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Abstract Health care costs represent a large and growing component of business and
consumer expenditures in the US. Medical inflation represents these costs, and it
differs from aggregate inflation and other market factors with respect to its rate of
growth, statistical properties and the extent to which it can be hedged by households
and firms. Using multiple model specifications for the 25-year period from 1985 to
2009, we find medical inflation is robustly priced in the cross-section of US stock
returns. It commands a risk premium of between 31 and 51 basis points per annum
per unit change in beta. Medical inflation is also unique in that it represents the only
inflationary component that robustly explains the cross-section of stock returns in this
manner and is not subsumed by other common factors in the literature. These results
quantify the health care industry’s unique and significant role in the US economy and
stock market, further rationalizing the substantial attention this industry receives.
Keywords Health care . Asset returns . Risk factors
JEL Classification G10 . G11 . G32
1 Introduction
Modern asset pricing theory seeks to find underlying economic, or risk, factors that
account for the temporal and cross-sectional variation in asset returns. The literature
has progressed from the aggregate market return as the only relevant factor (Sharpe
1964, and Lintner 1965, CAPM), to multifactor models based on the Ross (1976)
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arbitrage pricing theory (APT) or consumption (C-CAPM and ICAPM). Considering
health care costs as one such risk factor, we find medical inflation contributes to the
cross-section of stock returns even in the presence of previously considered factors.
The literature relating stock returns to aggregate inflation dates as early as Bodie
(1976), who finds an anomalous negative relation between stock returns and inflation.1
Fama (1981) and Geske and Roll (1983) argue that the observed relation between
inflation and stock returns is spurious. In contrast, Modigliani et al. (1979) offer a real
causal link between inflation and asset returns based on investor mispricing.
Incorporating US health care costs (i.e., medical inflation) into a factor pricing
model is materially different than previous research that has used aggregate inflation.
Medical inflation acts as a priced factor because of its unique impact on individual
consumption and firm cash flows. In the context of modern asset pricing theory,
investors attempt to smooth their consumption. Assets with returns that covary
positively with consumption are risky, while those that covary negatively with
consumption act as hedges. Within the context of the ICAPM, investors demand
assets with returns that covary positively with medical expenditures, and these assets
will command a lower expected return based on their hedging function. Traditionally,
consumption is modeled at the aggregate level; however, medical care consumption
warrants special treatment from other items in the consumption basket because of its
potential catastrophic impact on individuals and its high demand inelasticity. Rather
than use changes in medical consumption expenditures directly, we proxy medical
care consumption with the medical care component of the consumer price index
(CPI). Using the price index data in place of medical expenditures has the advantage
that medical inflation data are available monthly, which corresponds to the frequency
of our return data. Comparing the OECD figures for annual per person health care
expenditures to annual medical inflation figures supports this proxy decision. Be-
tween 1985 and 2008, per person health care expenditures in the US increased
approximately 6 % annually; annual medical inflation increased 5 % annually over
the same period. Thus the consumed quantity of medical expenditures changes at
approximately the same rates as medical inflation, and indeed the two annual series
are highly correlated with a Pearson value exceeding 0.80.
As for the justification to separate medical inflation from aggregate inflation, we
note medical inflation is distinct from aggregate inflation and its other components in
its degree, its statistical properties, its ability to be hedged, and its impact on
consumers and firms. The extreme level of the medical component of the CPI is
illustrated in Fig. 1. Although we recognize levels are not of ultimate interest, this
figure demonstrates the marked divergence of medical goods from others in the
consumption basket during the 25-year study period.
The medical component of the Consumer Price Index (CPI) breaks from the other
components of the CPI in approximately 1985. The CPI components in Fig. 1
currently represent almost 80 % of the aggregate CPI, with the Medical component
representing 6.39 %, Housing 43.42 %, Food 15.76 %, and Transportation 15.31 %.2
1 Other studies relating aggregate inflation and stock returns include Fama and Schwert (1977) and Schwert
(1981) for short-run relationships and Boudoukh and Richardson (1993) for long-term relationships.
2 While medical expenditures represent only 6.39 % of expenditures on average they are highly skewed,
with some individuals incurring catastrophic expenditures. The possibility of these extreme realizations is
one of the distinguishing characteristics of medical expenditures.
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Medical inflation also differs from other items in the CPI basket in terms of
individuals’ and firms’ ability to manage the associated costs. Certainly the use of
medical insurance allows consumers to partially “smooth” their consumption of
medical expenses over time. However, the empirical evidence on personal bankrupt-
cies suggests that even with insurance medical expenses are unique and cannot be
fully pooled. For example, Himmelstein et al. (2009) find 62 % of personal bank-
ruptcies filed in 2007 were linked to medical expenses even though nearly 80 % of
those filing for bankruptcy had health insurance. This rate of medical-cost-induced
personal bankruptcies has increased by almost 50 % since 2001.
The statistical properties and elasticities of medical expenses distinguish it from other
components of the CPI basket. The five components of Housing, Food, Energy, Educa-
tion and Transportation account for over 85% of the CPI. Unlike Food and Energy, which
have price movements that contain a large transitory component, shocks to medical
inflation are largely permanent.3 While shocks to Transportation can have a significant
impact on consumers, there are a variety of methods for hedging these shocks—for
example, public transportation, carpooling, or choosing less discretionary travel.4 Another
often discussed consumer good whose inflation outpaces aggregate inflation is Education.
However, one can manage education expenses over time by saving in advance or through
borrowing.5 Housing inflation has an ambiguous effect on consumers due to the asset
characteristics associated with housing and one’s ability to borrow against housing
appreciation. However, even accounting for the recent wide swing in housing prices,
the average annual real change in housing prices between 1948 and 2008 is just over one-
half percent; the 95th and 5th percentiles are 11 and −10 %, respectively. Thus, even
though Housing appreciation is skewed, it is much less so than medical expenditures. For
3 The transitory nature of Food and Energy prices is why they are removed when “core inflation” is
reported.
4 This analysis refers to the direct impact to consumers from transportation expenses. The input costs nature
of transportation inflation is embedded within other components of aggregate inflation to the extent
transportation expenses get passed on to consumers.
5 While one can save for incidental medical expenses through medical savings accounts, these funds must
be dispersed annually. It is doubtful one can borrow to cover medical expenses, particularly for terminal
illnesses.
Fig. 1 Consumer Price Index (CPI) levels. This Figure shows the monthly index levels for the aggregate
CPI (CPIAUCSL) and its major components: Medical CPI (CPIMEDSL), Housing CPI (CPIHOSSL), Food
CPI (CPIUFDSL), and Transportation CPI (CPITRNSL) from January 1967 to August 2009. Data comes
from the St. Louis Federal Reserve Economic Database (FRED)
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instance, in 2004 the average annual medical expenditures for individuals ages 19 to 64
were approximately $4,500. A single medical event such as a coronary bypass surgery
with 10 days of hospital stay can easily cost $50,000, or over 10 times the annual average.
To be clear, we are not arguing that the idiosyncratic risk to an individual consumer of
bearing high medical costs is a priced factor in the market. Rather, the consumer or
investor will pay a premium for assets that provide a hedge against medical shocks (i.e.,
assets that covary positively with medical inflation). The expected return on these assets
will reflect this covariance with medical inflation distinct from traditional factors such as
the market, SMB, or HML. We confirm this explanation in subsequent sections.
The above discussion illustrates howmedical inflation differs from other components
of inflation from the standpoint of the individual consumer. Medical inflation is also a
unique expense for firms relative to other input costs. Depending on the industry, firms
can manage many of the input costs by altering suppliers, changing product mixes, or
using formal commodity derivativemarkets.Managing labor costs—the avenue through
which medical inflation bears upon the firm—is more constrained. Firms can alter the
capital/labor production mix to some degree, use part-time workers who are not
compensated with health benefits, pass the cost onto customers, or relocate internation-
ally. The firm’s remaining medical expenses must be borne by the firm in the form of
lower cash flows.6
Medical expenses (i.e., inflation) are therefore different in magnitude and kind
from other consumer and business expenses. The ability of investors to diversify
away these expenses—or equivalently, whether the markets differentially price assets
that hedge medical inflation—poses an empirical question that the remainder of this
paper addresses using a standard factor pricing methodology.
2 Motivation and literature
We make three contributions to the literature. First, we present medical inflation as a
non-traditional macroeconomic factor for consideration in the context of prior asset
pricing theories. Given the economic impact on individuals (consumption) and firms
(earnings), health care costs merit consideration as a priced factor. While even recent
macroeconomic factor analysis (e.g., Aretz et al. 2010) argues for the use of
(unexpected) aggregate inflation as a factor, it does not discuss decomposing aggre-
gate inflation when the aggregate measure fails to price in the various specifications.
Our empirical analysis shows that the medical component of inflation is priced; other
components (e.g., housing, energy, transportation, food, or education) do not price.
We also extend prior empirical work, specifically Flannery and Protopapadakis
(2002), by analyzing their macroeconomic factors’ performance in a two-pass pricing
methodology. Medical inflation still prices in the presence of other macroeconomic
variables such as the Producer Price Index, M2 money supply, and housing starts. The
6 From the firm’s perspective, as a priced factor medical inflation imposes a risk-based cost on firms via
their cost-of-capital. The extent of this cost varies across firms depending on the magnitude of their medical
inflation (first-pass regression) betas. One way in which firms might alter their firm-specific risk is to
implement programs that incentivize more healthy living (e.g., wellness programs, paid exercise time, or
preventive medicine programs). Whether the cost is better borne by each firm in a decentralized fashion or
centrally through a social medical care system is another interesting question we leave for future research.
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finding that M2 and housing starts are also priced merits consideration for future
research, as we do not explore them further here. Finally, we construct a zero net
investment portfolio based on the relationship between firm returns and unexpected
medical inflation, finding it is priced even in the presence of the more common
characteristics-based factors of SMB, HML, and MOM.
Chen et al. (1986) present one of the earliest studies to extend factor pricing beyond
the single factor CAPM. Their use of macroeconomic factors, particularly aggregate
inflation, provides the initial specification we use to test medical inflation as a unique
factor. CRR use the Fama-MacBeth two pass regression method to test a multifactor
model which includes the market portfolio as one of the factors. Industrial production,
aggregate consumer inflation, and the term and default risk premiums constitute their
remaining factors. They find that the market return is not priced in the presence of other
macroeconomic factors. However, they find industrial production, default risk premia,
and yield curve differentials are priced factors in the multivariate setting, with expected
and unexpected aggregate inflation pricing during periods of volatility.
While CRR use economically-based factors, a more contemporary construct in-
cludes mimicking portfolios such as the Fama and French (1993) SMB, HML and the
Carhart (1997) MOM factors. We test whether the impact of medical inflation is
subsumed by these mimicking portfolios, finding that medical inflation is a robustly
priced factor across a wide variety of specifications even in the presence of these
macroeconomic and characteristic-based factors.
For robustness purposes we also extend a later study, in which Flannery and
Protopapadakis (2002) perform the first-pass regression of the Fama and MacBeth
(1973) procedure using 17 macroeconomic series. A similar effort by Cenesizoglu
(2011) focuses on macroeconomic variables’ sensitivity to the business cycle, inves-
tigating the daily return effects of news for 21 macroeconomic series. Neither study
decomposes inflation into its sub-components, so we extend these findings by (1)
including medical inflation as one of several macroeconomic series and (2)
performing the associated Fama-MacBeth second-pass regressions. Among others,
medical inflation represents a priced factor in the presence of these more recently
proposed macroeconomic factors.
In another robustness test, we create a zero net investment portfolio factor by
differencing the returns for quintiles of stocks with high and low medical inflation
betas. We again find evidence suggesting medical inflation is a priced factor in asset
returns; the more common SMB, HML, and MOM factors do not subsume this
“medical HML” factor. Finally, we examine other components of aggregate inflation,
namely Housing, Energy, Transportation, and Education & Communication as priced
factors in a similar manner to Medical inflation. None of these other components
demonstrate universal pricing behavior akin to Medical inflation. Overall, this em-
pirical evidence supports medical care costs as a priced factor.
3 Medical care inflation data
Based on when medical care inflation begins its systematic deviation from other
inflationary components, our sample begins in January 1985 and ends in August
2009, for a total of 296 months of data. This sample period represents the time when
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Medical CPI begins a trend of 25 years of month-to-month variation that deviates
substantially from aggregate inflation and its other non-Medical components. Expla-
nations vary as to why health care costs begin a dramatic rise starting in the mid-
1980s, but White (2007) presents data indicating that structural factors in the US
drive high health care costs relative to other OECD countries. Specifically, by
subdividing the data into pre- and post-1985 time periods, White’s study concludes
that the relatively late onset of insurance, financing health care costs through private
insurers versus a centralized public authority, and a focus on the quality of service
versus cost containment all play a role in the relatively high US health care costs.
All series in our study are seasonally-adjusted when possible. All monthly and
quarterly percent changes are stationary; the only exceptions are annual Food and
Transportation inflation, which exhibit explosive growth in some periods. For the
remainder of the analysis we use monthly percent changes for inflation and convert
discrete asset returns to their continuous values by differencing the natural log values
of the series levels.
We decompose medical inflation into its expected and unexpected components
using a Kalman Filter procedure originally described by Ansley (1980) and used in
Fama and Gibbons (1982) and as recently as Aretz et al. (2010). Figures 2 and 3 show
the plot of ex-post aggregate and medical inflation, respectively, along with their
expected counterparts derived using this Kalman Filter method. The expected series
are smoothed versions of the respective ex-post inflation series. We construct unex-
pected inflation as the difference between ex-post inflation and the expected inflation
measures from the Kalman Filter.
Table 1 presents the correlations among unexpected medical inflation and other
potential factors that could contain the same information such as unexpected
CPIAUCMO EXPINF
1970 1975 1980 1985 1990 1995 2000 2005
-2.0
-1.5
-1.0
-0.5
0.0
0.5
1.0
1.5
2.0
Fig. 2 Ex-post and expected aggregate inflation using Kalman Filter model. This figure shows the time
series of ex-post monthly aggregate inflation (CPIAUCMO) versus the expected monthly aggregate
inflation (EXPINF) from January 1967 to August 2009. The expected monthly inflation series is calculated
based on the relationship between inflation and interest rates according to a Kalman Filter methodology
developed by Ansley (1980) as described in Fama and Gibbons (1982). This procedure permits the constant
within a regression model to change dynamically based on past data trends in an effort to discern the
difference between the true signal and “noise” associated with the signal. In this analysis, the expected
inflation component represents the signal, and the unexpected component is the “noise”
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aggregate inflation and the term premium (TERM). Unexpected medical inflation is
essentially uncorrelated with unexpected aggregate inflation and with the term
premium, with values of −0.014 and 0.029, respectively. These low correlations
provide further evidence that unexpected medical inflation does not simply reflect
shocks to aggregate inflation. For subsequent robustness purposes, Table 1 also
shows correlation values between unexpected medical inflation and shocks to other
components of aggregate inflation, such as housing, energy, transportation, food, or
education and communication. These relatively low values indicate medical inflation
shocks differ from those of other economic sectors. Additionally, motivated by both
the Stock and Watson (2001) vector auto regression (VAR) technique and the Fama
and Gibbons (1984) moving average technique, for robustness we also calculate
unexpected medical inflation using the residuals from three- to eight-variable VAR
specifications and a 6-month trailing moving average. All the proxies for unexpected
inflation are highly correlated with each other and importantly, uncorrelated with the
other risk factors used in the next section. Additionally, all cross-sectional relation-
ships shown in future tables hold for these various manners of estimating unexpected
medical inflation.
4 Methodology and results
4.1 Health care as a priced risk
In this section we apply a rolling Fama and MacBeth (1973) two-pass methodology
to determine whether medical care inflation shocks explain the cross-section of
returns across the broader market. We use the 25 size and book-to-market Fama-
CPIMEDMO EXPMEDINF
1970 1975 1980 1985 1990 1995 2000 2005
-1.0
-0.5
0.0
0.5
1.0
1.5
2.0
Fig. 3 Ex-post and expected medical inflation using Kalman Filter model. January 1967-August 2009. This
figure shows the time series of ex-post monthly medical inflation (CPIMEDMO) versus the expected monthly
medical inflation (EXPMEDINF) from January 1967 to August 2009. The expected monthly inflation series is
calculated based on the relationship between inflation and interest rates according to a Kalman Filter
methodology developed by Ansley (1980) as described in Fama and Gibbons (1982). This procedure permits
the constant within a regression model to change dynamically based on past data trends in an effort to discern
the difference between the true signal and “noise” associated with the signal. In this analysis, the expected
inflation component represents the signal, and the unexpected component is the “noise”
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French portfolios as test assets in this analysis.7 In addition to market risk, these
portfolios capture two features of asset risk that persist across a wide variety of
models. In the first pass, we use 60 months of returns to estimate beta values for each
of the 25 portfolios. In a single-factor model, for instance, completing this first pass
provides 25 beta values. Incorporating additional factors increments the beta count in
multiples of 25 (e.g., a three-factor model yields 25 beta values per factor, or 75 total).
During the second pass, we run 12 cross-sectional regressions (CSRs) to estimate the
monthly price of these betas over the 12 months immediately following the beta
estimation period. For example, beginning with 25 Fama and French portfolio beta
estimations from January 1980 to December 1984, we estimate 12 monthly cross-
sectional regressions from January to December 1985. We then increment both the
beta estimation period and CSR pricing period by 12 months using the rolling-beta
technique (e.g., beta estimation occurs from January 1981 to December 1985 with
CSRs occurring from January to December 1986). Using cross-sectional data begin-
ning in January 1985 and ending in August 2009, we obtain 296 monthly risk
premium estimates. We then test whether the average risk premium is statistically
different from zero or “priced” using the time series of respective risk premia. All risk
premia are tested using both the unadjusted standard error and the rolling-beta EIV-
adjusted asymptotic standard error method described in Shanken (1992a).8
We use three major specifications for the first-pass regression. First we augment
the CRR (1986) model specifications to include medical inflation components, which
results in five total CRR-related specifications. Next, in a hybrid macroeconomic-
characteristics model, we price the Fama and French (1993) five factors, include
momentum, and augment these factors with medical inflation for a total of seven
related specifications. For macroeconomic robustness, we extend the more recent
results of Flannery and Protopapadakis (2002) by including medical inflation to their
list of potential macroeconomic factors in five more specifications. Since their study
identifies other potential macroeconomic factors, we complete the second-pass factor
pricing test for their candidate factors and find that medical inflation shocks remain a
priced factor controlling for these additional macroeconomic factors. Finally, for a
characteristics-based application, we create a medical inflation factor using return
differences between portfolios with high versus low unexpected medical inflation
betas. Unexpected medical inflation is a priced factor in every specification it enters,
while aggregate medical inflation is priced in all but two of its applicable
specifications.
Table 2 presents second-pass results when we augment the CRR (1986) model to
include medical inflation as a factor. The specifications represent the CRR baseline
7 We thank Ken French for this data: http://mba.tuck.dartmouth.edu/pages/faculty/ken.french/data_
library.html.
8 As a preliminary screen, we decompose the covariance structure of the 25 Fama-French portfolios using
principal components analysis. Similar to Chen, Roll and Ross (CRR) (1986), we use the five principal
components associated with the five largest eigenvectors to represent the underlying return factor structure.
CRR state that “An economic variable is significantly related to stock movements if and only if it is
significantly related to at least one of the common stock factors.” We regress the five extracted factors
against expected medical inflation, the excess market return, SMB, and HML. We strongly reject that the
slope coefficient on unexpected medical inflation is jointly zero across the five equations. Unexpected
medical inflation is related to the fourth and second principal component at the 0.001 and 0.121 levels,
respectively. We proceed with a more in-depth analysis for the remainder of the paper.
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and four model permutations. In the baseline specification (column 1), both the term
and default risk premium, DEF and TERM, are priced in support of CRR, while none
of the other factors are priced. Column 2 augments the basic CRR model specifica-
tion, which implements the first-difference of expected aggregate inflation as well as
aggregate inflation shocks, with the medication inflation analogs—both the first-
difference of expected medical inflation as well as the unexpected medical inflation
series. Unexpected (aggregate) medical inflation prices negatively at the five (ten)
percent level even in the presence of (non-priced) expected and unexpected aggregate
inflation; both DEF and TERM maintain their pricing. This negative sign on unex-
pected medical inflation is consistent with the ICAPM hedging role of assets. Assets
that covary positively with medical inflation act like a hedge and therefore investors
are willing to forego expected return for this hedging benefit. In addition, the
magnitude of the coefficient on unexpected medical inflation is similar across the
specifications indicating that unexpected medical inflation is nearly orthogonal to the
other control variables and measures a distinct priced factor.
Comparable to CRR, specifications 3 and 5 control for the market’s influence by
including the value-weighted market return premium (MKTRF) as a factor. In spec-
ification 3, unexpected medical inflation is priced negatively, and it is robust to the
inclusion of the market factor. Adding the market factor does not affect the economic
Table 2 Macroeconomic factors, two-pass results for priced factors
Specification 1 2 3 4 5
Constant 1.075*** 1.071*** 1.488*** 1.057*** 1.679***
ΔEXPMED −0.002 −0.004
UNEXPMED −0.040** −0.040**
CPIMED −0.040* −0.041*
MKTRF −1.017** −1.188***
INDPRO −0.057 0.004 −0.035 0.017 −0.020
ΔEXPINF −0.005 −0.002 −0.004 −0.005 −0.006
UNEXPINF 0.023 0.027 0.026 0.026 0.010
DEF −0.143** −0.153** −0.136** −0.138** −0.104
TERM 0.319* 0.326* 0.365** 0.332* 0.337**
N= 296 296 296 296 296
This Table depicts results from the second-pass of the Fama and MacBeth (1973) rolling regression
procedure to assess priced risk factors in stock returns. Macroeconomic factors are based on Chen et al.
(1986). Results are from the sample period of January 1985 to August 2009 for 296 months’ worth of
pricing data. The beta estimation period is 60 months. Test assets are the 25 Fama-French quintile-sorted
size and book-to-market portfolios. ΔEXPMED is the first-differenced series (i.e., time t minus time t-1) of
medical inflation. UNEXPMED is the unexpected component of medical inflation as determined by a state
space model described in Fama and Gibbons (1982). CPIMED is monthly medical inflation, or the sum of
expected and unexpected medical inflation.MKTRF is the market return net of the risk-free rate (taken from
Ken French’s Data Library). INDPRO is the monthly change in Industrial Production. ΔEXPINF is the first-
differenced series (i.e., time t minus time t-1) of aggregate inflation. UNEXPINF is analogous to
UNEXPMED for aggregate inflation. DEF is the difference between the 10-year Treasury bond and a
portfolio of Baa corporate bonds. TERM is the difference between the 10-year Treasury bond and the 90-
day Treasury bill. Standard errors (and p-values) are EIV-adjusted using the Shanken (1992a) methodology
***, **, * indicate significance at the 1 %, 5 %, and 10 % levels
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significance (magnitude of the coefficient) of medical inflation shocks.9 Specifica-
tions 4 and 5 substitute aggregate ex-post medical inflation (CPIMED) for expected
and unexpected medical inflation and find overall ex-post medical inflation also
prices significantly (negative), and the magnitude remains similar across specifica-
tions. We lose DEF as a priced factor in the final specification that includes CPIMED
and MKTRF, but only slightly with a p-value of 0.119.
Overall, accounting for medical inflation in the CRR (1986) analysis strengthens
the evidence that market participants demand return premia for exposure to medical
inflation, and the impact on the expected return of this demand is insensitive to
whether we account for the market return or other control variables.
While the prior specification concentrates solely on other macroeconomic factors,
the next test involves augmenting, with medical inflation, three model specifications
based on the Fama-French SMB and HML return-based factors. Table 3 presents the
results of these second-pass regressions. Specification 1 is the baseline specification
for a three-factor model. The first three subsequent specifications include both first-
differenced expected medical inflation and unexpected medical inflation
(UNEXPMED) while augmenting the three-factor model with DEF, TERM, and the
Carhart (1997) MOM factor. The final three specifications replace expected and
unexpected medical inflation with ex-post medical inflation (CPIMED).
As with prior results, unexpected medical inflation and ex-post medical inflation
price negatively across all specifications. The economic significance remains similar
to earlier findings and supports the hypothesis that the market recognizes the rele-
vance of medical care costs, particularly unexpected ones. Notably, specification 3
shows that unexpected medical inflation is significant in explaining the cross-section
of returns at the 1 % significance level. Once again, MKTRF prices negatively over
the past 25 years while TERM continues to price positively. Additionally, HML prices
positively across specifications, while in contrast to the earlier CRR (1986) results,
DEF fails to price in any of them. Finally, SMB and MOM both fail to price in any
specification where they are included. The evidence in Tables 2 and 3 supports
unexpected medical inflation as a non-diversifiable source of risk over the past
25 years even in the presence of the well-known Fama and French (1993) and
momentum factors.
4.2 Robustness: additional factor models
We next extend the work of Flannery and Protopapadakis (2002), who use unexpect-
ed shocks to 17 macroeconomic series as candidates for priced risk factors but do not
investigate the effect of medical inflation. We focus on the Flannery and
Protopapadakis macroeconomic variables that they argue should be most considered
in a pricing analysis given their first-pass results. These variables include the monthly
9 The market factor prices significantly (negative) in columns 3 and 5, which while contrary to economic
theory, the findings are not unique to our study. For instance, CRR show negatively-signed (insignificant)
prices for value-weighted market returns in their overall period and two of three sub-periods, as do Hahn
and Lee (2006) for their specifications and time period. Additionally, Fama and French (1992a) show
negatively-signed market risk pricing, which becomes statistically significant for individual stocks in the
most recent decade of their study, which ends in 1990. The negative pricing for the market portfolio does
not appear isolated to a particular time period or study.
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percentage changes in (aggregate) producer price index for all commodities (PPI
(Agg)), the producer price index for crude materials (PPI(Crude)), the M1 and M2
money supplies, and total new housing starts (HOUST). We include ex-post aggregate
inflation components for control purposes.
Table 4 depicts the results using this subset of the Flannery and Protopapadakis
(2002) macroeconomic variables. Specification 1 shows the baseline model, resulting
in priced factors that include unexpected aggregate inflation, (UNEXPINF: positive),
the producer price index, (PPI(Agg): positive), and M2 money stock (negative).
Adding medical inflation components in the second specification shows it prices
negatively yet also affects the pricing behavior of the crude materials component of
the producer price index, PPI(Crude), which also now prices (positively). The third
specification removes the crude component due to the risk of redundancy between it
and the producer price index for all commodities. Unexpected medical inflation still
prices negatively. The results for ex-post medical inflation (CPIMED) in specifica-
tions 4 and 5 deviate from those shown earlier. In the aggregate, while still
Table 3 Characteristics factors, two-pass results for priced factors
Specification 1 2 3 4 5 6 7
Constant 1.197*** 1.022*** 1.495*** 1.576*** 1.172*** 1.523*** 1.593***
ΔEXPMED −0.004 −0.003 −0.003
UNEXPMED −0.036** −0.043*** −0.038**
CPIMED −0.041** −0.049** −0.039*
MKTRF −0.762** −0.558* −1.026*** −1.105*** −0.721** −1.078*** −1.135***
SMB −0.037 −0.022 −0.014 −0.004 −0.024 −0.016 −0.006
HML 0.379* 0.367* 0.339* 0.332* 0.370* 0.345* 0.349*
DEF −0.029 −0.065 −0.079 −0.107
TERM 0.491*** 0.439** 0.424*** 0.346**
MOM −0.333 −0.163
N= 296 296 296 296 296 296 296
This Table depicts results from the second-pass of the Fama and MacBeth (1973) rolling regression
procedure to assess priced risk factors in stock returns. Characteristics factors are from Fama and French
(1993) and Carhart (1997). Results are from the sample period of January 1985 to August 2009 for
296 months’ worth of pricing data. The beta estimation period is 60 months. Test assets are the 25
Fama-French quintile-sorted size and book-to-market portfolios. ΔEXPMED is the first-differenced series
(i.e., time t minus time t-1) of medical inflation. UNEXPMED is the unexpected component of medical
inflation as determined by a state space model described in Fama and Gibbons (1982). CPIMED is
aggregate medical inflation, or the sum of expected and unexpected medical inflation. MKTRF is the
market return net of the risk-free rate. SMB is calculated by subtracting the return of the decile of the largest
stocks—by market capitalization—from the decile of smallest stocks. HML is calculated by subtracting the
return of the stock decile having the lowest book-to-market equity ratio from the decile with the highest
book-to-market ratio. See Fama and French (1993) for additional details regarding MKTRF, SMB, and
HML. DEF is the difference between the 10-year Treasury bond and a portfolio of Baa corporate bonds.
TERM is the difference between the 10-year Treasury bond and the 90-day Treasury bill. MOM is a
momentum factor found by subtracting the returns of a stock portfolio having the lowest recent returns from
a portfolio having the highest recent returns. MKTRF, SMB, HML, and MOM are from Ken French’s Data
Library. Standard errors (and p-values) are EIV-adjusted using the Shanken (1992a) methodology
***, **, * indicate significance at the 1 %, 5 %, and 10 % levels
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negatively-signed, ex-post medical inflation does not price significantly as it does in
earlier specifications. Thus, the behavior of these other macroeconomic factors, while
perhaps subsuming aggregated ex-post medical inflation, does not obviate the rele-
vance of medical inflation shocks. Noteworthy is the consistent pricing behavior of
both the PPI(Agg) and the M2 money stock. Both of these results present an avenue
for future research. Overall, controlling for the Flannery and Protopapadakis (2002)
results, we still find evidence that even accounting for these additional macroeco-
nomic factors, unexpected medical inflation remains priced at conventional statistical
levels. Risk premia remain approximately the same magnitude as those shown in
prior tables, on the order of 0.03 % per month or approximately 36 basis points per
year, for a one-unit-change in medical inflation beta.
Even though medical inflation remains priced as a macroeconomic factor along-
side the zero net investment portfolios listed previously, we next test whether the
pricing phenomenon is sensitive to the form of the medical inflation factor. Instead of
using the medical inflation shock as a factor, we form a high-medical beta minus low-
medical beta (MedHML) factor and determine whether it is priced in equilibrium. We
Table 4 Macroeconomic factor candidates, two-pass results for priced factors
Specification 1 2 3 4 5
Constant 0.560* 0.631* 0.831** 0.423 0.534
ΔEXPMED 0.004 0.003
UNEXPMED −0.026* −0.028*
CPIMED −0.025 −0.021
ΔEXPINF 0.007 0.008 0.008 0.005 0.003
UNEXPINF 0.051* 0.057** 0.043 0.053* 0.040
PPI (Agg) 0.215** 0.281*** 0.238** 0.227** 0.201*
PPI (Crude) 0.410 1.085* 0.425
M1 −0.084 −0.080 −0.079 −0.105 −0.123
M2 −0.108** −0.100** −0.100** −0.117** −0.109**
HOUST −2.905** −2.562** −2.320* −2.778** −2.893**
N= 296 296 296 296 296
This Table depicts results from the second-pass of the Fama and MacBeth (1973) rolling regression
procedure to assess priced risk factors in stock returns. Macroeconomic factor candidates are from Flannery
and Protopapadakis (2002). Results are from the sample period of January 1985 to August 2009 for
296 months’ worth of pricing data. The beta estimation period is 60 months. Test assets are the 25 Fama-
French quintile-sorted size and book-to-market portfolios. ΔEXPMED is the first-differenced series (i.e.,
time t minus time t-1) of medical inflation. UNEXPMED is the unexpected component of medical inflation
as determined by a state space model described in Fama and Gibbons (1982). CPIMED is aggregate
medical inflation, or the sum of expected and unexpected medical inflation. ΔEXPINF is the first-
differenced series (i.e., time t minus time t-1) of aggregate inflation. UNEXPINF is analogous to
UNEXPMED for aggregate inflation. PPIAgg (PPICrude) is the monthly change in Producer Price Index
for all commodities (crude materials).M1 (M2) is the monthly change in M1 (M2) Money Stock, seasonally
adjusted.HOUST is the monthly change in total new housing starts. The prior 5 series are from the St. Louis
Federal Reserve Federal Reserve Economic Database (FRED). MKTRF is the market return net of the risk-
free rate from Ken French’s Data Library. Standard errors (and p-values) are EIV-adjusted using the
Shanken (1992a) methodology
***, **, * indicate significance at the 1 %, 5 %, and 10 % levels
J Econ Finan (2015) 39:153–170 165
form portfolios of securities based on their covariance with unexpected medical
inflation. We pull from CRSP all stocks that have at least 60 months of returns
between January 1967 and December 2008, resulting in 16,093 firms. From these we
draw a random sample of 3,000 firms. Beginning in January 1980, we perform time-
series regressions of individual firm returns on medical inflation shocks, expected
medical inflation, SMB, HML, DEF, TERM, and MOM for 60 months. We then order
the firms based on the resulting beta associated with unexpected medical inflation and
use this ordering for the ensuing 12 months. Note that this sorting measures the
sensitivity to medical inflation surprises while controlling for return sensitivity to the
other factors. We create quintiles of these stocks ordered by unexpected medical
inflation beta and calculate an equally-weighted monthly average of returns in each
quintile. Differencing the average returns of the high-beta quintile and low-beta
quintile forms our MedHML factor. We roll the beta estimation period forward by
12 months and repeat the process. In the end we generate 288 MedHML factors
between January 1985 and December 2008.
We incorporate MedHML as a factor in the Fama-MacBeth two-pass procedure to
determine whether it is priced. The first-pass results are given in Table 5, Panel A.
Although this specification also includes MKTRF, SMB, HML, DEF, TERM, and
MOM, we present only the values for MedHML. These results indicate that MedHML
covaries significantly with the Fama-French 25 portfolio returns for 14 of the 25
portfolios at conventional significance levels. Additionally, the covariance is positive
for firms in the smallest quintile and then changes sign as firms grow in size. All else
equal, smaller firms correlate more (i.e., more significantly more often) over time
with medical inflation shocks than larger firms. The covariance is not as monotonic
on the B/M scale; extreme growth (i.e., low B/M) and value (i.e., high B/M)
portfolios generally fail to covary significantly with the MedHML factor.
The second-pass results are located in Table 5, Panel B. The result found in earlier
specifications persists, as MedHML again prices negatively. Firms that covary posi-
tively with medical risk act as hedges and thus sacrifice expected return due to their
risk reducing (ICAPM hedging) contribution.10 The market prices a zero investment
medical inflation risk factor similarly to how it prices the macroeconomic medical
inflation measure, that is, with a negative premium. Thus our finding of the market
pricing the risk associated with health care costs is robust to creating a firm
characteristics-based factor in addition to the macroeconomic factor analyzed earlier.
4.3 Robustness: other inflation components
A natural follow-up question is whether the negative risk premium associated with
medical inflation is unique to medical inflation shocks or whether it also occurs with
10 We examined the relationship between medical inflation and the health care industry. Time series
regressions over the sample period in this study show significantly negative relationships between medical
inflation shocks and returns to firms in the health care industry. The same relationship holds for the
pharmaceuticals sub-industry, which represents approximately 80 % of the larger health care industry.
Health services (7 %) and medical equipment (13 %) represent the balance of the larger health care industry.
All of these time series regressions control for the market risk premium, SMB, HML, MOM, DEF, TERM,
and aggregate inflation factors. Health care industry and sub-industry results are the 5- and 48-industry
return series, respectively, found in Ken French’s data library. Results are available upon request.
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Table 5 Characteristics-based medical inflation factor
Parameter values Size
Small 2 3 4 Big
Panel A: First-Pass Results for βMedHML, January 1985-December 2008
B/M Low 16.49 −2.40 −2.40 −0.48 −2.99
2 5.22 −10.25 −4.41 −8.00 −7.45
3 1.49 −5.02 −7.84 −6.12 −4.09
4 4.52 −7.68 −5.73 −8.80 −1.25
High 5.95 −7.21 −3.02 −0.79 4.39
T-Statistics
B/M Low 4.07 −0.81 −0.84 −0.18 −1.34
2 1.78 −3.76 −1.42 −2.48 −2.67
3 0.62 −1.98 −2.66 −1.86 −1.31
4 1.79 −3.06 −2.00 −3.03 −0.48
High 2.26 −2.75 −0.88 −0.22 1.08
Panel B: Second-Pass Results, January 1985-December 2008
Constant 1.882***
MedHML −0.006*
MKTRF −1.286***
SMB 0.019
HML 0.483**
DEF 0.103
TERM 0.122
MOM 1.667***
N= 288
…,25, t represents time, k represents the number of factors, and Zi represents a factor used to explain returns. βp,i
represents a portfolio-specific parameter estimated in the model and is calculated as the covariance of the factor
results from the second-pass of the Fama and MacBeth (1973) rolling regression procedure to assess priced risk
factors in stock returns for the overall period and two sub-periods. For this specification, the portfolios p are the
Fama and French size- and book-to-market sorted quintiles, t represents the 288 months spanning from January
1985 to December 2008, and the factors k are described as follows.MedHML is the return formed by subtracting
the returns of a portfolio having a low beta with medical inflation from the returns of a portfolio having a high
beta with medical inflation. These portfolios are formed by sorting individual stocks into quintiles based on their
medical inflation beta. The estimated values are shown in the upper table, and the by-portfolio t-statistics are
shown in the lower table. The following factors, while included, are not displayed:MKTRF is the market return
net of the risk-free rate. SMB is calculated by subtracting the return of the decile of the largest stocks—by market
capitalization—from the decile of smallest stocks.HML is calculated by subtracting the return of the stock decile
having the lowest book-to-market equity ratio from the decile with the highest book-to-market ratio. See Fama
and French (1993) for additional details regardingMKTRF, SMB, and HML. DEF is the difference between the
10-year Treasury bond and a portfolio of Baa corporate bonds. TERM is the difference between the 10-year
Treasury bond and the 90-day Treasury bill. MOM is a momentum factor found by subtracting the returns of a
stock portfolio having the lowest recent returns from a portfolio having the highest recent returns. Shading
indicates parameters that are significant at the 10 % level. In Panel B p-values are below parameter values
***, **, * indicate significance at the 1 %, 5 %, and 10 % levels
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This Table depicts the factor pricing results using a characteristics-based medical inflation factor for the period
January 1985 to December 2008. Panel A shows results for the Fama and MacBeth (1973) first-pass regression
for the following model: Rp;t ¼ a0 þ
Pk
i¼1
bp;iZi;t þ ut where Rp,t is the montht excess return on portfolio p, p=1,
and portfolio return normalized by the variance of the factor (i.e., bp;i ¼ cov R p;ið Þ;Zi
 
var Zið Þ= . Panel B depicts
other CPI components. Table 6 summarizes the results for medical inflation and other
CPI components, namely Housing, Energy, Transportation, Food, and Education and
Communication. This last component becomes available beginning in January 1993,
while the others have remained CPI components for the entire January 1985 to
August 2009 period. We select two specifications from each of Tables 3, 4 and 5 to
summarize the results, using the same Kalman Filter method as with Medical
inflation to extract the respective shocks to the various other inflation components.
While medical inflation prices negatively in all specifications, at best, Transpor-
tation inflation prices in three of the specifications during this same post-1985 period.
The sign remains consistently and counterintuitively—from the ICAPM hedging
perspective—positive for Transportation inflation. There is little evidence for Food
inflation pricing negatively, but none of the other inflationary component shocks
show signs of pricing in the past 25 years. The Education and Communication result
is somewhat surprising given this inflationary component outpaces aggregate infla-
tion during its (shorter) period of existence, much like Medical inflation. However,
we posit these shocks are not as demand inelastic as health care in that individuals
have real options when it comes to Education consumption (i.e., delay or abandon
getting a degree) that will allow them to smooth consumption in a manner that
trivializes the impact on required asset returns.
Given the impact of medical inflation on asset returns in the US, one area of future
research would be to find investable assets that act as a hedge against medical
inflation. Jennings et al. (2009) begin such an investigation. Counter-intuitively, they
find that health care-focused mutual funds are not natural hedges for medical infla-
tion. Payne (2010) implements an iterative Genetic Algorithm approach to find
parsimonious hedging portfolios of individual stocks and bonds. Although the out-
of-sample results are encouraging, more extensive analysis appears warranted. Con-
sistent with prior studies related to aggregate inflation, no particular industries or firm
Table 6 Summary of second-pass results for various types of inflation
Unexpected
xxx Inflation:
CRR (86)
no MKTRF
(Table 2,
column 2)
CRR (86)
incl MKTRF
(Table 2,
column 3)
FF (93)
no MOM
(Table 3,
column 3)
FF (93)
incl MOM
(Table 3,
column 4)
FP (02) incl
PPI(Crude)
(Table 4,
column 2)
FP (02) no
PPI(Crude)
(Table 4,
column 3)
Medical Negative Negative Negative Negative Negative Negative
Housing – – – – – –
Energy – – – – – –
Transportation – – Positive Positive Positive –
Food – – Negative – – –
Education &
Communicationa
– – – – – –
This Table depicts the statistically-significant (10 % level) unexpected components and signs of various
inflation series in the US for the period January 1985 to August 2009 using OLS standard errors. The model
specifications correspond to the indicated studies and our earlier Tables. CRR refers to Chen et al. (1986),
FP refers to Flannery and Protopapadakis (2002), and FF refers to Fama and French (1993). The two-pass
pricing methodology follows Fama and MacBeth (1973)
a Results for pricing period January 1998-August 2009 since data series begins January 1993
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types consistently hedge medical inflation. Another area for future research includes
health care’s role as a priced factor in other countries. Such international comparisons
are useful in assessing the robustness of underlying investor attributes across coun-
tries and cultures. While medical inflation contrasts with these underlying attributes
due to its entanglement with institutional structures and the delivery of medical
services that are unique to many countries, cross-country comparisons could help
identify which institutional structures drive the results in this paper.
5 Conclusion
Health care represents a major component of the US economy. In the past quarter-
century its costs have risen much faster than the balance of the economy as measured by
the CPI. Despite these escalating costs, firms have shown resilience in their commitment
to provide medical care as an employee benefit. Even in the presence of medical
insurance, catastrophic medical expenses represent a real bankruptcy risk to individuals.
Consequently, individuals would price assets that covary positively with medical
inflation at a premium due to their hedging benefit. In addition, to the extent firms are
exposed to medical costs differently (i.e., more or less employees, better or worse health
care plans, more or less leverage when negotiating rates with providers), their cash flows
change as this component of their cost structure changes. And if investors cannot
diversify away this risk across firms, they will demand excess returns for bearing the
risk of escalating medical expenses that firms evidently will not or cannot trim.
This study sheds light on whether the US stock market considers medical care costs a
source of non-diversifiable risk. By separating the medical inflation component from the
other basket of goods that composes aggregate inflation, we generate a macroeconomic
factor to test these questions. Looking at monthly returns for the period between January
1985 and August 2009, we use the earlier factor model by Chen et al. (1986) as a
baseline to show medical inflation’s behavior in the cross-section. We also expand the
analysis to incorporate the findings regarding macroeconomic factors from Flannery and
Protopapadakis (2002) as well as the mimicking factors developed in Fama and French
(1993). We augment these models to include an expected and unexpected medical
inflation component. Our findings support the contention that (unexpected) medical
inflation represents a priced risk factor over the past 25 years and commands a risk
premium of between 31 and 51 basis points per annum per unit change in beta. We also
show that a mimicking factor based on stock returns’ relationship with medical inflation
also explains the cross-section of returns over this period. Finally, we find this relation-
ship is unique to the medical component of inflation, as neither aggregate inflation nor
any of its other components significantly explain the cross-section of returns as consis-
tently as the medical component. Due to its role in the US economy and—as we find—
in the US stock market, it is no surprise the health care industry receives the high level of
political and popular attention that it does.
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